US Copper Firms Hike Prices Even After Trump Tariff Reprieve
Southwire Co. LLC, one of the largest makers of copper wire and cable in the US, and Cerro Wire LLC, a wiremaker owned by Berkshire Hathaway Inc., in recent days announced price increases of 5% across a range of copper wire products, according to a Bloomberg calculation based on their published price sheets.
Chicago Schools Seeks $1 Billion of Short-Term Debt as Cash Gone
A Photographer's Pipe Dream: Capturing New York's Vast Water System
A London Apartment Tower With Echoes of Victorian Rail and Ancient Rome
Why New York City Has a Fleet of New EVs From a Dead Carmaker
Princeton Plans New Budget Cuts as Pressure From Trump Builds
The move shows how a small group of low-profile companies that own US copper-processing plants are likely to be the primary beneficiaries of Trump's shock tariff reprieve.
The president's decision to apply his 50% import tariff only to manufactured goods containing copper such as wires and cables, and not to unprocessed refined copper as widely expected, means companies like Southwire and Cerrowire will now be paying much less than they feared for the metal they purchase. At the same time, the import tariff on copper containing goods raises costs for their international competitors shipping products to the US.
And until the US builds more copper processing plants, the added cost on the hundreds of thousands of tons of copper-containing goods it imports each year is likely to be inflationary for US consumers despite a sharp drop in domestic prices for copper itself, analysts say.
'While wire and cable prices are influenced by copper prices, they are not the same. The margin between the two can widen if local producers have more pricing power,' said Aisling Hubert, senior wire and cable analyst at consultancy CRU Group. The tariff means that US producers will have the upper hand in price negotiations with their customers, she said.
It's not clear whether the price increases were a direct response to the tariff decision, and it's likely to take some time before the full effects on the market are clear.
Domestic prices for copper wire and cable — used in almost every building, electronic device, and power utility — had already risen sharply before Trump's decision, according to US government data. An index of prices that forms part of the calculation of producer price inflation hit a record high in July, up 12% from a year earlier.
Neither Southwire nor Cerrowire responded to requests for comment. Southwire, which is one of the largest importers of refined copper into the US, lobbied against tariffs on refined copper imports in a letter to the Department of Commerce earlier this year.
Massimo Battaini, chief executive of Prysmian SpA, which together with Southwire dominates the US wire and cable market, said the tariff decision had been a relief and would likely mean higher profits for his company.
Speaking on a conference call with analysts the day after the announcement, he said: 'Local producers, like we are, will benefit from cost of cables imported from overseas much higher than today. So this will certainly benefit our guidance, our forecast for the full year.'
The US imported 810,000 tons of unprocessed copper last year, accounting for 45% of the country's consumption of 1.8 million tons, according to US Geological Survey data.
While those imports are spared from tariffs, the US also imports hundreds of thousands of tons of copper-containing goods, which are now set to be subject to 50% duties. That includes semi-processed products like copper rod, pipe, tube and sheet, and finished goods like cables. Of the total US cable demand last year, 23% was met by imports.
To be sure, US companies may invest in more domestic capacity to replace imports, reducing the inflationary effect of the tariff. Cable imports would be 'difficult to replace in the short term' but new capacity for low-voltage cable can be built in 1-2 years, said Hubert at CRU.
What's more, there's significant uncertainty about how broadly the tariffs will be applied. It isn't clear whether imports from Canada and Mexico, two of the main sources of imports of copper products, would be exempt from the new tariffs under the free trade agreement between the three countries, according to Hubert.
Analyst at JPMorgan Chase & Co. said that the US was significantly less dependent on imports of copper products than on refined copper, making the buildout of additional domestic capacity 'likely relatively achievable in the coming years.' Still, they predicted 'higher end-use prices' in the meantime.
Peter Schmitz, director of global copper markets research at Wood Mackenzie, said that copper accounted for about two thirds of the cost of a cable and 20%-30% of the cost of an electrical motor.
'Is it inflationary? Yes it is,' he said of the tariffs. 'Ultimately somebody pays; that is going to be the American consumer.'
Foreigners Are Buying US Homes Again While Americans Get Sidelined
What Declining Cardboard Box Sales Tell Us About the US Economy
Women's Earnings Never Really Recover After They Have Children
Americans Are Getting Priced Out of Homeownership at Record Rates
Yosemite Employee Fired After Flying Trans Pride Flag
©2025 Bloomberg L.P.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Masimo sues US Customs over approval of Apple Watch imports
By Blake Brittain WASHINGTON (Reuters) -Medical monitoring technology company Masimo sued U.S. Customs and Border Protection on Wednesday over a decision by the agency that allowed Apple to import Apple Watches with blood-oxygen reading technology during a patent dispute between the companies. Masimo said in the lawsuit in Washington, D.C., federal court that Customs improperly determined that Apple can import watches with pulse oximetry technology, reversing its own decision from last year without notifying Masimo. Masimo told the court that it learned of the agency's August 1 decision only after Apple announced it would reintroduce blood-oxygen reading to its watches last week. Spokespeople for Apple and Customs did not immediately respond to requests for comment. A Masimo spokesperson declined to comment. Irvine, California-based Masimo has accused Apple of hiring away its employees and stealing its pulse oximetry technology to use in its Apple Watches. Masimo has separately sued Apple for patent infringement and trade secret theft in ongoing federal court cases. Masimo convinced the U.S. International Trade Commission to block imports of Apple's Series 9 and Ultra 2 smartwatches in 2023 based on a determination that Apple's technology for reading blood oxygen levels infringed Masimo's patents. Apple has continued to sell Customs-approved redesigned watches without pulse oximetry since the ITC's decision. Apple said on Aug. 14 that it would reintroduce its smartwatches' blood-oxygen reading capabilities with approval from Customs. Masimo said the agency's decision to approve the watches without input from Masimo or any "meaningful justification" deprived the company of its rights. "CBP's function is to enforce ITC exclusion orders, not to create loopholes that render them ineffective," Masimo said. Masimo asked the Washington court to halt the agency's ruling and continue to block Apple from selling watches with the blood-oxygen feature. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 minutes ago
- Yahoo
Why Medtronic Stock Raced Higher Today
Key Points Investors traded out of the company the previous day following its latest earnings release. The stock came roaring back on Hump Day, however. 10 stocks we like better than Medtronic › A clutch of post-earnings price target increases by analysts helped raise Medtronic's (NYSE: MDT) stock at a healthy rate on Wednesday. The sturdy medical device specialist's shares rose by almost 4% on the day as a consequence, a rate that looked especially good next to the S&P 500's (SNPINDEX: ^GSPC) 0.2% drop. Healthy raises Following a trend that began Tuesday after Medtronic published its first quarter of fiscal 2026 figures. The company posted revenue growth of 8% (to almost $8.6 billion), and improved non-GAAP (generally accepted accounting principles) adjusted net income by 2% to slightly over $1.6 billion. Both headline numbers beat the consensus analyst estimates, albeit not by much. The market, which collectively loves a crushing beat on analyst estimates, basically shrugged at this. Many investors traded out of Medtronic that day. The sun was shining brighter on Wednesday thanks to that series of price target bumps. By my count, seven analysts tracking the stock upped their fair-value assessments. Among these were pundits at such financial industry heavyweights as Wells Fargo, J.P. Morgan, and international bank UBS. Positive moves from cautious pundits I should note that in all cases, those price target raises were incremental. Nevertheless, the raising analysts frequently sounded bullish notes on Medtronic's prospects. One example was Leerink Partners' Mike Kratky, who only added $1 per share for a new level of $111, but maintained his outperform (read: buy) recommendation. According to reports, Kratky praised several elements of the company's operations, particularly its cardiac ablation solutions unit. Less positively, the analyst wrote that Medtronic suffered from weakness in its domestic sales. Should you invest $1,000 in Medtronic right now? Before you buy stock in Medtronic, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Medtronic wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $654,781!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,076,588!* Now, it's worth noting Stock Advisor's total average return is 1,055% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Wells Fargo is an advertising partner of Motley Fool Money. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy. Why Medtronic Stock Raced Higher Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 minutes ago
- Yahoo
Florida sues textbook giants for alleged $60M fraud: '5900 instances of Overcharges,' governor says
The state has filed a lawsuit seeking to claw back millions of dollars from two of the nation's largest textbook publishing companies.